Analysts at Drexel Hamilton started coverage on shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in a research report issued on Tuesday. The brokerage set a “buy” rating on the stock.
A number of other research firms have also commented on TNXP. Aegis started coverage on Tonix Pharmaceuticals Holding Corp. in a research report on Monday, June 26th. They issued a “buy” rating and a $10.00 price target on the stock. Roth Capital upgraded Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Friday, August 18th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $7.50.
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) opened at 3.29 on Tuesday. The firm has a 50-day moving average of $3.78 and a 200 day moving average of $3.37. The company’s market capitalization is $24.70 million. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $2.85 and a 12 month high of $28.00.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.13. On average, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post ($3.02) earnings per share for the current fiscal year.
In related news, CEO Seth Lederman purchased 20,000 shares of Tonix Pharmaceuticals Holding Corp. stock in a transaction on Tuesday, June 20th. The shares were purchased at an average price of $4.22 per share, for a total transaction of $84,400.00. Following the transaction, the chief executive officer now owns 7,912 shares of the company’s stock, valued at approximately $33,388.64. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ernest Mario sold 6,105 shares of the company’s stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $4.28, for a total value of $26,129.40. Following the completion of the sale, the director now owns 63,073 shares in the company, valued at approximately $269,952.44. The disclosure for this sale can be found here. Insiders acquired a total of 50,000 shares of company stock worth $188,050 in the last quarter. Corporate insiders own 4.00% of the company’s stock.
Several large investors have recently added to or reduced their stakes in TNXP. Renaissance Technologies LLC raised its stake in shares of Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock valued at $364,000 after buying an additional 402,898 shares during the last quarter. B. Riley Financial Inc. acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter valued at approximately $1,637,000. Vanguard Group Inc. raised its stake in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock valued at $799,000 after buying an additional 41,264 shares during the last quarter. Dialectic Capital Management LP acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter valued at approximately $187,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter valued at approximately $119,000. Hedge funds and other institutional investors own 17.50% of the company’s stock.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
